2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Regeneron Pharmaceuticals, Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #123 · 再生元製藥公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | REGN |
| Company | Regeneron Pharmaceuticals, Inc. |
| GICS sector / industry | Health Care (XLV) / Biotechnology |
| S&P 500 rank (by weight) | #123 · 0.14% (Oct 30, 2026) |
| Sector rank | #20 in Health Care (Oct 30, 2026) |
| Headquarters | Tarrytown, New York |
| Founded | 1988 |
| CEO | Leonard Schleifer (Co-founder and CEO) |
| Employees | 15,410 |
| Market cap | $95.53B (Oct 30, 2026) |
| Share price | $927.89 (Oct 30, 2026) |
| SEC filings | EDGAR — CIK 0000872589 |
WHAT IT DOES
Regeneron Pharmaceuticals is a biotechnology company that discovers, invents and sells its own medicines, built on proprietary technology platforms rather than acquisitions. Its one-line model: turn in-house science — above all its VelociSuite antibody platforms and its genetics center — into patented drugs sold at specialty prices.
Revenue combines net product sales with collaboration revenue, mainly Regeneron's share of profits from its Sanofi partnership. In FY2025 collaboration revenue of $7.33B exceeded net product sales of $6.31B, so partner economics now matter as much as the company's own price tags.
The economics are those of a hit-driven drug developer: very high margins on successful antibodies, heavy and continuous R&D spending, and value concentrated in a few franchises — EYLEA in eye disease and Dupixent in immunology — whose patents and competition set the stock's story.
BUSINESS SEGMENTS
| EYLEA franchise | Aflibercept injections (EYLEA and EYLEA HD) for wet age-related macular degeneration, diabetic macular edema and other retinal diseases; first approved by the FDA in November 2011. |
| Dupixent | Dupilumab for atopic dermatitis and other type 2 inflammatory diseases, developed and commercialized with Sanofi, which records global net sales; first approved in March 2017. |
| Libtayo | Cemiplimab, a PD-1 inhibitor for cutaneous squamous cell carcinoma and other cancers; first approved in September 2018. |
| Other marketed products | Praluent (cholesterol), Kevzara (rheumatoid arthritis), Arcalyst, Zaltrap, Inmazeb (Ebola) and Veopoz (CHAPLE disease), among others. |
| Platforms & genetics | The VelociSuite technologies (including VelocImmune) that generate fully human antibodies, and the Regeneron Genetics Center, which has sequenced over 3 million exomes. |
EYLEA franchise Aflibercept injections (EYLEA and EYLEA HD) for wet age-related macular degeneration, diabetic macular edema and other retinal diseases; first approved by the FDA in November 2011.
Dupixent Dupilumab for atopic dermatitis and other type 2 inflammatory diseases, developed and commercialized with Sanofi, which records global net sales; first approved in March 2017.
Libtayo Cemiplimab, a PD-1 inhibitor for cutaneous squamous cell carcinoma and other cancers; first approved in September 2018.
Other marketed products Praluent (cholesterol), Kevzara (rheumatoid arthritis), Arcalyst, Zaltrap, Inmazeb (Ebola) and Veopoz (CHAPLE disease), among others.
Platforms & genetics The VelociSuite technologies (including VelocImmune) that generate fully human antibodies, and the Regeneron Genetics Center, which has sequenced over 3 million exomes.
HISTORY
| Year | Milestone |
|---|---|
| 1988 | Leonard Schleifer and George Yancopoulos found Regeneron in New York, focused on neurotrophic factors and regenerative medicine. |
| 2011 | The FDA approves EYLEA (aflibercept) in November 2011; it becomes the company's first blockbuster. |
| 2017 | The FDA approves Dupixent (dupilumab) in March 2017, opening the immunology franchise built with Sanofi. |
| 2020 | Regeneron's REGN-COV2 antibody cocktail receives FDA emergency use authorization for COVID-19 in November 2020. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT
| Total revenue | $14.34B (FY2025 total revenues) |
| Operating income | $3.58B (FY2025 operating income) |
| Net income | $4.50B (FY2025 net income) |
| Diluted EPS | $41.48 (FY2025 diluted EPS) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Regeneron is a small-weight health-care constituent: rank #123 by weight at 0.14% as of Oct 30, 2026, and #20 in Health Care. Its results are read as a gauge of specialty-drug pricing power and of how far a science-led, acquisition-free biotech model can scale.
SOURCES & METHODOLOGY
| Financials, segments, headquarters | Regeneron fiscal 2025 Form 10-K (year ended December 31, 2025) |
| Index weight & ranks | Slickcharts S&P 500 weights, Oct 30, 2026 close, fetched Oct 31, 2026 (dispatch baseline, used verbatim) |
| Market cap | $95.53B (Oct 30, 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Chart | SPXSet chart library, monthly bars, compiled from Yahoo public information. |
The chart plots 119 monthly bars from Nov 2016 to Sep 2026. The window's monthly high was $1,211.20 in Aug 2024 and its low $271.37 in Sep 2019; Sep 2026 closed at $758.27.
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | REGN |
| 公司 | Regeneron Pharmaceuticals, Inc.(再生元製藥) |
| GICS 板塊/行業 | 醫療保健(XLV)/生物科技 |
| 標普500排名(按權重) | #123 · 0.14%(Oct 30, 2026) |
| 板塊內排名 | 醫療保健 #20(Oct 30, 2026) |
| 總部 | 美國紐約州塔里敦 |
| 成立 | 1988年 |
| 執行長 | Leonard Schleifer(共同創辦人兼執行長) |
| 員工 | 15,410 |
| 市值 | $95.53B(Oct 30, 2026) |
| 股價 | $927.89(Oct 30, 2026) |
| SEC 申報 | EDGAR — CIK 0000872589 |
業務概覽
再生元製藥是一家生物科技公司,自行發現、發明並銷售藥物,依靠自有技術平台而非收購成長。其一句話商業模式是:把內部科學——尤其是 VelociSuite 抗體平台與基因中心——轉化為以專科藥價格出售的專利藥物。
收入由淨產品銷售與合作收入組成,合作收入主要為與 Sanofi 夥伴關係的利潤分成。FY2025 合作收入 73.3 億美元,已超過淨產品銷售 63.1 億美元,夥伴經濟學的重要性已不下於公司自身的定價。
其經濟學是爆款藥驅動的藥物開發模式:成功抗體藥毛利極高,研發投入沉重而持續,價值集中於少數旗艦產品——眼科的 EYLEA 與免疫的 Dupixent——其專利與競爭決定股價故事。
業務板塊
| EYLEA 系列 | 阿柏西普注射劑(EYLEA 與 EYLEA HD),用於濕性老年黃斑部病變、糖尿病黃斑水腫及其他視網膜疾病;2011 年 11 月首獲 FDA 批准。 |
| Dupixent | 度匹魯單抗,用於異位性皮膚炎及其他第二型炎症疾病,與 Sanofi 共同開發及商業化,全球淨銷售由 Sanofi 入帳;2017 年 3 月首獲批准。 |
| Libtayo | 西米普利單抗,PD-1 抑制劑,用於皮膚鱗狀細胞癌及其他癌症;2018 年 9 月首獲批准。 |
| 其他上市產品 | Praluent(膽固醇)、Kevzara(類風濕性關節炎)、Arcalyst、Zaltrap、Inmazeb(伊波拉)與 Veopoz(CHAPLE 病)等。 |
| 平台與基因 | VelociSuite 技術(包括 VelocImmune)用於生成全人源抗體;再生元基因中心已完成逾 300 萬個外顯子定序。 |
EYLEA 系列 阿柏西普注射劑(EYLEA 與 EYLEA HD),用於濕性老年黃斑部病變、糖尿病黃斑水腫及其他視網膜疾病;2011 年 11 月首獲 FDA 批准。
Dupixent 度匹魯單抗,用於異位性皮膚炎及其他第二型炎症疾病,與 Sanofi 共同開發及商業化,全球淨銷售由 Sanofi 入帳;2017 年 3 月首獲批准。
Libtayo 西米普利單抗,PD-1 抑制劑,用於皮膚鱗狀細胞癌及其他癌症;2018 年 9 月首獲批准。
其他上市產品 Praluent(膽固醇)、Kevzara(類風濕性關節炎)、Arcalyst、Zaltrap、Inmazeb(伊波拉)與 Veopoz(CHAPLE 病)等。
平台與基因 VelociSuite 技術(包括 VelocImmune)用於生成全人源抗體;再生元基因中心已完成逾 300 萬個外顯子定序。
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1988 | Leonard Schleifer 與 George Yancopoulos 在紐約創立再生元,專注神經營養因子與再生醫學。 |
| 2011 | FDA 於 2011 年 11 月批准 EYLEA(阿柏西普),成為公司的首個重磅產品。 |
| 2017 | FDA 於 2017 年 3 月批准 Dupixent(度匹魯單抗),開啟與 Sanofi 合作的免疫業務。 |
| 2020 | 再生元的 REGN-COV2 抗體雞尾酒療法於 2020 年 11 月獲 FDA 緊急使用授權用於 COVID-19。 |
競爭地位
財務快照
| 總收入 | $14.34B(FY2025 總收入) |
| 營業利潤 | $3.58B(FY2025 營業利潤) |
| 淨利潤 | $4.50B(FY2025 淨利潤) |
| 稀釋 EPS | $41.48(FY2025 稀釋 EPS) |
主要風險
對標普500的重要性
再生元製藥是權重較小的醫療保健成分股:按權重排名 #123,權重 0.14%(以 Oct 30, 2026 為準),醫療保健板塊內排名 #20。其業績被視為專科藥定價能力,以及科學主導、不靠收購的生技模式能走多遠的指標。
來源與方法
| 財務、板塊、總部 | 再生元製藥 2025 財年 Form 10-K(截至 2025 年 12 月 31 日) |
| 指數權重與排名 | Slickcharts 標普500權重,Oct 30, 2026 收盤,Oct 31, 2026 抓取(派工基線,原文引用) |
| 市值 | $95.53B(Oct 30, 2026) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 股價圖 | SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
本圖繪製 2016 年 11 月至 2026 年 9 月共 119 根月 K。期間月線最高 $1,211.20(2024 年 8 月)、最低 $271.37(2019 年 9 月);2026 年 9 月收於 $758.27。
來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-31 07:06 · updated 2026-11-14 23:58 · rev 6